Dear Sam Surette:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see
https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-
combination-products); good manufacturing practice requirements as set forth in the quality systems (QS)
regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for
combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-
542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part
807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part
803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-
mdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including
information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-
devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn
(https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the
Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See
the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-
assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE
by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

[Signature]

For

Thalia T. Mills, Ph.D.
Director
Division of Radiological Health
OHT7: Office of In Vitro Diagnostics
and Radiological Health
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure
Caption Guidance

Indications for Use (Describe)

The Caption Guidance software is intended to assist medical professionals in the acquisition of cardiac ultrasound images. The Caption Guidance software is an accessory to compatible general purpose diagnostic ultrasound systems.

The Caption Guidance software is indicated for use in two-dimensional transthoracic echocardiography (2D-TTE) for adult patients, specifically in the acquisition of the following standard views: Parasternal Long-Axis (PLAX), Parasternal Short-Axis at the Aortic Valve (PSAX-AV), Parasternal Short-Axis at the Mitral Valve (PSAX-MV), Parasternal Short-Axis at the Papillary Muscle (PSAX-PM), Apical 4-Chamber (AP4), Apical 5-Chamber (AP5), Apical 2-Chamber (AP2), Apical 3-Chamber (AP3), Subcostal 4-Chamber (SubC4), and Subcostal Inferior Vena Cava (SC-IVC).

Type of Use (Select one or both, as applicable)

☒ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
Name of Device: Caption Guidance

Classification Name: Image Acquisition And/Or Optimization Guided By Artificial Intelligence

Regulatory Class: II

Product Code: QJU

Predicate Device: Caption Guidance (DEN190040)

Device Description:

The Caption Guidance software is a radiological computer assisted acquisition guidance system that provides real-time user guidance during acquisition of echocardiography to assist the user in obtaining anatomically correct images that represent standard 2D echocardiographic diagnostic views and orientations. Caption Guidance is a software-only device that uses artificial intelligence to emulate the expertise of sonographers.

Caption Guidance is comprised of several different features that, combined, provide expert guidance to the user. These include:

- **Quality Meter**: The real-time feedback from the Quality Meter advises the user on the expected diagnostic quality of the resulting clip, such that the user can make decisions to further optimize the quality, for example by following the prescriptive guidance feature below.

- **Prescriptive Guidance**: The prescriptive guidance feature in Caption Guidance provides direction to the user to emulate how a sonographer would manipulate the transducer to acquire the optimal view.
• **Auto-Capture**: The Caption Guidance Auto-Capture feature triggers an automatic capture of a clip when the quality is predicted to be diagnostic, emulating the way in which a sonographer knows when an image is of sufficient quality to be diagnostic and records it.

• **Save Best Clip**: This feature continually assesses clip quality while the user is scanning and, in the event that the user is not able to obtain a clip sufficient for Auto-Capture, the software allows the user to retrospectively record the highest quality clip obtained so far, mimicking the choice a sonographer might make when recording an exam.

**Intended Use / Indications for Use:**

The Caption Guidance software is intended to assist medical professionals in the acquisition of cardiac ultrasound images. The Caption Guidance software is an accessory to compatible general purpose diagnostic ultrasound systems.

The Caption Guidance software is indicated for use in two-dimensional transthoracic echocardiography (2D-TTE) for adult patients, specifically in the acquisition of the following standard views: Parasternal Long-Axis (PLAX), Parasternal Short-Axis at the Aortic Valve (PSAX-AV), Parasternal Short-Axis at the Mitral Valve (PSAX-MV), Parasternal Short-Axis at the Papillary Muscle (PSAX-PM), Apical 4-Chamber (AP4), Apical 5-Chamber (AP5), Apical 2-Chamber (AP2), Apical 3-Chamber (AP3), Subcostal 4-Chamber (SubC4), and Subcostal Inferior Vena Cava (SC-IVC).

**Summary of Technological Characteristics:**

The Caption Guidance software is an updated version of the predicate device and features very similar technological characteristics. The modified version included device enhancements designed to increase usability and performance. This includes additional prescriptive guidance for the users, information for users via the UI, optimized quality meter and automated image capture, ability to set the scanning convention to that of the user’s facility, ability to set custom protocols and skip certain portions of protocols at the user’s discretion.

None of the differences raise different questions of safety or effectiveness and available data demonstrate that the current iteration of the Caption Guidance software performs in a substantially equivalent manner.

**Performance Data**

The Caption Guidance software was developed and tested in accordance with Caption Health’s Design Control processes and has been subjected to extensive safety and performance testing.

Caption Guidance was identified as having a moderate level of concern as defined in the FDA guidance document “Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices.” The software documentation included:

1. Software/Firmware Description
2. Device Hazard Analysis
Risk analysis was provided for the software with detailed description of the hazards, their causes and severity as well as acceptable methods for control of the identified risks. Caption Health provided a description, with test protocols including pass/fail criteria and report of results, of acceptable verification and validation activities at the unit, integration and system level.

Extensive algorithm development and software verification testing assessed the performance of the software. Images and cases used for verification testing were carefully separated from training algorithms. The Caption Guidance algorithm was tested for the performance of the modified Auto-Capture feature in recording clinically-acceptable images and clips. Furthermore, the subject device’s algorithm was tested for the performance of providing Prescriptive Guidance (PG), using the following tasks:

1. Frame-level PG prediction of the probe maneuver needed to acquire an image/frame of heart, for a specific view.
2. Clip-level PG prediction of the probe maneuver needed to acquire a diagnostic quality clip for a specific view.

Overall, the non-clinical performance testing results provide evidence in support of the functionality of Caption Guidance fundamental algorithms.

Additionally, the modified Caption Guidance underwent additional human factors testing. Caption Guidance has undergone preliminary formative evaluations, as well as final summative testing that assesses the critical tasks potentially impacted by the modification to the prescriptive guidance features. While risk assessment and formative testing concluded that no new critical tasks were introduced, two existing critical tasks were implicated by the changes. Summative testing has been completed with 16 users (7 users without prior scanning experience and 9 users with prior experience). The summative human factors testing concluded that there were no use errors associated with critical tasks likely to lead to patient injury. Additionally, although the testing was not comparative in nature, when viewed in context of the testing provided in the original De Novo, the enhanced product appears to provide optimization of usability.

Taken together, the performance testing demonstrates that the Caption Guidance software performs as expected and in a manner that is substantially equivalent to the predicate device.
Conclusions

The current iteration of the Caption Guidance software is as safe and effective as the previous iteration of such software. The Caption Guidance software has the same intended uses and similar indications, technological characteristics, and principles of operation as its predicate device. In addition, the minor technological differences between the current iteration of the Caption Guidance software and the previous iteration of the Caption Guidance software raise no new issues of safety or effectiveness. Performance data demonstrate that the current iteration of the Caption Guidance software is as safe and effective as the previous iteration of the Caption Guidance software. Thus, the Caption Guidance software is substantially equivalent.